Knight Therapeutics Inc T.GUD

Alternate Symbol(s): KHTRF

Healthcare

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.

TSX:GUD - Post by User

Knight Therapeutics Inc > Nov 11 - release its third quarter 2021 financial results

<< Previous

Bullboard Posts

Next >>

Comment by Chianchinon Nov 10, 2021 7:56am

68 Views

Post# 34108721

RE:RE:RE:RE:RE:RE:RE:RE:Nov 11 - release its third quarter 2021 financial results

Tomorrow is GUD last show the market last chance after years of torrid $$$ down drain results. If it does not more heads will roll by next May if not all of them. MNGT and BOD

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023